Why Castle Biosciences, Inc.’s (CSTL) Stock Is Up 5.53%
As of Wednesday, August 19, Castle Biosciences, Inc.’s CSTL share price has surged by 5.53%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Stock Evaluator: Castle Biosciences, Inc. (CSTL)
Castle Biosciences, Inc. CSTL
$32.32
3.29
11.33%
August 19, 2026 4:00:00 PM
EST
Volume: 451,917
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Commentary & Analysis
Is Castle Biosciences, Inc. (CSTL) Overvalued?
We dive into why Castle Biosciences, Inc. (CSTL) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why Castle Biosciences, Inc.’s (CSTL) Stock Is Up 5.61%
As of Monday, August 03, Castle Biosciences, Inc.’s CSTL share price has surged by 5.61%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Castle Biosciences, Inc.’s (CSTL) Stock Is Up 10.83%
As of Friday, July 31, Castle Biosciences, Inc.’s CSTL share price has surged by 10.83%, which has investors questioning if this is right time to sell.Michael Rose
Why Castle Biosciences, Inc.’s (CSTL) Stock Is Up 12.09%
As of Friday, July 31, Castle Biosciences, Inc.’s CSTL share price has surged by 12.09%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | CSTL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $987.4 | $1,958.8 | 45% |
|
| Shares Out (Mil) | 30.4 | 77.7 | 37% |
|
| Institutional Ownership | 97.2% | 86.1% | 73% |
|
| Float (Mil) | 27.1 | 52.1 | 34% |
|
| Beta | na | 0.76 | na |
|
| Avg Daily Volume (000s) | 413 | 637 | 55% |
|
| Price Change (52-week) |
57.2% | 79.4% | 82% |
|
| Growth | CSTL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 40.6% | 10.9% | 94% |
|
| Net Income (5yr) | (18.6%) | (1.6%) | 21% |
|
| EPS (5yr) | (8.9%) | 0.3% | 22 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (17.9%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.358) | ($1.272) | ($0.989) | |
| Month Ago EPS | ($0.301) | ($1.417) | ($0.957) | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 3 | 0 | 0 | |
| Three Months Ago EPS | ($0.280) | ($1.359) | ($0.901) | |
| Year/Year Chg | 411.4% | 52.7% | (56.5%) | |
| Financials | CSTL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $357 | $1,504 | 38% |
|
| Net Income (TTM) (Mil) | ($19) | $28 | 24% |
|
| EPS (TTM) | ($0.654) | $0.200 | 25% |
|
| Operating Cash Flow (TTM) (Mil) | $43 | $162 | 45% |
|
| Net Cash Flow (TTM) (Mil) | ($20) | $9 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $32 | $338 | 36% |
|
| Enterprise Value (Q1) (Mil) | na | $2,445 | na |
|
| Valuation | CSTL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.10 | 2.78 | 52% |
|
| P/E | na | 26.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CSTL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.3% | 27.8% | 87% |
|
| Net Margin | (5.4%) | 1.2% | 25% |
|
| ROA | (3.5%) | 2.2% | 32% |
|
| ROE | (4.2%) | 7.2% | 31% |
|
| Liabilities to Assets | 16.2% | 58.6% | 10% |
|
| F-Score | 3 | 5 | 18% |
|
Castle Biosciences, Inc. did not pass any screens on 8/19/2026.
